dc.contributor.author | Johnson, DC | |
dc.contributor.author | Lenive, O | |
dc.contributor.author | Mitchell, J | |
dc.contributor.author | Jackson, G | |
dc.contributor.author | Owen, R | |
dc.contributor.author | Drayson, M | |
dc.contributor.author | Cook, G | |
dc.contributor.author | Jones, JR | |
dc.contributor.author | Pawlyn, C | |
dc.contributor.author | Davies, FE | |
dc.contributor.author | Walker, BA | |
dc.contributor.author | Wardell, C | |
dc.contributor.author | Gregory, WM | |
dc.contributor.author | Cairns, D | |
dc.contributor.author | Morgan, GJ | |
dc.contributor.author | Houlston, RS | |
dc.contributor.author | Kaiser, MF | |
dc.date.accessioned | 2017-11-24T13:40:38Z | |
dc.date.issued | 2017-10-05 | |
dc.identifier.citation | Blood, 2017, 130 (14), pp. 1639 - 1643 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/951 | |
dc.identifier.eissn | 1528-0020 | |
dc.identifier.doi | 10.1182/blood-2016-11-750612 | |
dc.description.abstract | Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, we analyzed whole exome sequencing tumor data for 333 patients from Myeloma XI, a UK phase 3 trial and 434 patients from the CoMMpass study, all of which had received immunomodulatory drug (IMiD) therapy. By analyzing mutant allele frequency distributions in tumors, we found that 17% to 20% of MM is under neutral evolutionary dynamics. These tumors are associated with poorer patient survival in nonintensively treated patients, which is consistent with the reduced therapeutic efficacy of microenvironment-modulating IMiDs. Our findings provide evidence that knowledge of the evolutionary history of MM has relevance for predicting patient outcomes and personalizing therapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 1639 - 1643 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER SOC HEMATOLOGY | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Multiple Myeloma | |
dc.subject | Thalidomide | |
dc.subject | Immunosuppressive Agents | |
dc.subject | Immunologic Factors | |
dc.subject | Prognosis | |
dc.subject | Gene Frequency | |
dc.subject | Genetic Drift | |
dc.subject | Mutation | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Tumor Microenvironment | |
dc.subject | Exome | |
dc.subject | Lenalidomide | |
dc.title | Neutral tumor evolution in myeloma is associated with poor prognosis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-08-07 | |
rioxxterms.versionofrecord | 10.1182/blood-2016-11-750612 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Blood | |
pubs.issue | 14 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.publication-status | Published | |
pubs.volume | 130 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Myeloma Biology and Therapeutics | |
icr.researchteam | Cancer Genomics | |
icr.researchteam | Myeloma Group | |
dc.contributor.icrauthor | Pawlyn, Charlotte | |
dc.contributor.icrauthor | Kaiser, Martin | |